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Intestinal remodeling and stricture formation is a com-
plication of inflammatory bowel disease (IBD) that of-
ten requires surgical intervention. Although eosino-
phils are associated with mucosal remodeling in other
organs and are increased in IBD tissues, their role in
IBD-associated remodeling is unclear. Histological and
molecular features of ileitis and remodeling were as-
sessed using immunohistochemical, histomorphomet-
ric, flow cytometric, and molecular analysis (real-time
RT-PCR) techniques in a murine model of chronic eosi-
nophilic ileitis. Collagen protein was assessed by Sircol
assay. Using a spontaneous eosinophilic Crohn’s-like
mouse model SAMP1/SkuSlc, we demonstrate an asso-
ciation between ileitis progression and remodeling over
the course of 40 weeks. Mucosal and submucosal eosin-
ophilia increased over the time course and correlated
with increased histological inflammatory indices. Ileitis
and remodeling increased over the 40 weeks, as did
expression of fibronectin. CCR3-specific antibody-medi-
ated reduction of eosinophils resulted in significant de-
crease in goblet cell hyperplasia, muscularis propria
hypertrophy, villus blunting, and expression of inflam-
matory and remodeling genes, including fibronectin.
Cellularity of local mesenteric lymph nodes, including
T- and B-lymphocytes, was also significantly reduced.
Thus, eosinophils participate in intestinal remodel-
ing, supporting eosinophils as a novel therapeutic
target. (Am J Pathol 2011, 179:2302–2314; DOI:
10.1016/j.ajpath.2011.07.039)
2302Intestinal remodeling is a complex process that in health
results in mucosal healing and in disease leads to patho-
logical consequences that include stricture formation.
Stricture formation is a common complication of inflam-
matory bowel disease (IBD), occurring in up to 30% of
patients with Crohn’s disease and occasionally in ulcer-
ative colitis.1 Although current therapeutic strategies ad-
dress inflammation, treatment of strictures most fre-
quently involves surgical resection.2
Inflammatory bowel disease has traditionally been as-
sociated with lymphocytes, NKT cells, dendritic cells,
macrophages, and neutrophils,3 but a growing body of
evidence supports functional roles also for eosinophils in
IBD.4–6 To date, clinical evidence demonstrating the im-
portance of eosinophils in IBD has been limited to histo-
logical analysis and peripheral biomarker measurements.
Lampinen et al7 reported that eosinophil numbers were
increased in active disease, compared with normal con-
trol subjects. Other studies documented evidence of eo-
sinophilia in IBD with increased numbers of eosinophils
and eosinophil products in the mucosa and stool of pa-
tients with IBD.5,7–9 Although eosinophils are increased
during inflammation in IBD,5 a clear role for them in the
pathogenesis of IBD has not been elucidated.
Murine studies have defined a role for eosinophils in
acute colonic inflammation.8,10,11 The strongest evidence
supporting a pathogenic role for eosinophils in intestinal
remodeling measured acute inflammation in the murine
dextran sulfate sodium (DSS) colitis model. Forbes et al12
demonstrated that eosinophil peroxidase (EPO)-null mice
were protected from 8 days of DSS colitis. Similarly,
Shichijo et al13 identified a key role for another eosinophil
granule protein, eosinophil cationic protein (ECP), in
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role for major basic protein (MBP) in intestinal epithelial
barrier disruption after 7 days of colonic inflammation.14
Eosinophil-null mice (PHIL and dblGATA) are relatively
protected from DSS colitis, compared with wild-type con-
trols,8,11 providing strong evidence for the participation of
eosinophils in the early stages of intestinal inflammation.
Finally, in a study transmitting ileitis via adoptive transfer
of CD4 T cells from Th1-cytokine-driven SAMP1/Yit mice
into immunodeficient SCID mice injected therapeutically
with antibody to the critical eosinophilopoietin IL-5,
Takedatsu et al15 showed improved ileo-colonic inflam-
mation. In that study, the contribution of eosinophils to
remodeling was not addressed; however, the authors
provided evidence for the importance of eosinophils in
mediating the initiation of ileal inflammation in this
adoptive transfer system. To date, no other study has
directly addressed the role of eosinophils in chronic
inflammation and remodeling in vivo.
IBD-associated fibrosis is a multifactorial process,1,6
and although animal models indicate a role for eosino-
phils in acute colonic inflammation, little is known regard-
ing the role of eosinophils in chronic ongoing ileitis or in
intestinal remodeling, such as is found in patients with
Crohn’s disease. In this regard, eosinophils remain
sources of mediators associated with fibrosis and are
commonly detected in inflamed and fibrotic tissues in
diseases at other sites, as well as in the gastrointestinal
tract.16 Eosinophils secrete a number of profibrotic me-
diators, including members of the transforming growth
factor-beta family (TGF-s), fibroblast growth factors,
matrix metallopeptidases (MMPs), and profibrotic cyto-
kines (including IL-13).17,18 Targeted reduction of eosin-
ophils in patients with asthma reduces pulmonary rem-
odeling.19 Patients with eosinophilic esophagitis can
develop esophageal strictures and remodeling.17,20
On the basis of these observations, we hypothesized
that eosinophilic inflammation contributes to ileal remod-
eling. To date, no other study has directly addressed the
role of eosinophils in chronic spontaneous inflammation
and remodeling in vivo. Because very few mouse models
of chronic spontaneous IBD exist, we performed a 40-
week longitudinal study defining the characteristics of
remodeling in the original Th2-SAMP1 mouse model of
chronic ileitis. Our data suggest that eosinophils play a
role in ileal remodeling and that in patients with IBD the
therapeutic targeting of eosinophils may lead to reduc-
tions in remodeling events that lead to stricture formation,
which subsequently requires surgery.
Materials and Methods
Mice
Original SAMP1 strain SAMP1/SkuSlc21 female mice 4 to
10 weeks of age were purchased from Japan SLC
(Hamamatsu, Japan). SAMP1 mice were derived from
brother-sister mating of AKR/J mice. AKR mice (AKR/J;
a/a Tyrc/Tyrc Soat1ald/Soat1ald hid/hid), which have been
described previously,22 were purchased from the Jack-son Laboratory (Bar Harbor, ME) and served as nonin-
flamed controls. Mice were maintained under specific
pathogen-free conditions with ad libitum access to food
and water. Mouse studies were approved by the Univer-
sity of Colorado Denver Institutional Animal Care and Use
Committee.
Intestinal Permeability Assay
For assessment of intestinal permeability, mice were
orally gavaged with a solution of 80 mg/mL fluorescein
isothiocyanate (FITC)-labeled dextran (4 kDa; Sigma-Al-
drich, St Louis, MO) as described previously.23 Mice
were sacrificed 4.5 hours after administration and whole
blood was collected. Serum was isolated and placed in
triplicate into a 96-well plate. Presence of FITC-dextran
was assessed by fluorometric techniques and was quan-
tified against a standard curve of FITC-labeled dextran.
Dexamethasone Treatment
For dexamethasone treatment studies, mice were in-
jected intraperitoneally with 100 g dexamethasone
(Vedco, St. Joseph, MO) in a volume of 200 L every
second day from 20 weeks of age for 10 days.10 Control
mice were injected intraperitoneally with an equal volume
of saline at equal frequency and duration.
Anti-CCR3 Treatment
Anti-CCR3 rat anti-mouse monoclonal antibody 6S2-19-4
selectively depletes murine eosinophils.24,25 This anti-
body has been shown to selectively target cells with
sufficient density of receptor on their surface for comple-
ment mediated cell lysis.25,26 For antibody inhibition stud-
ies, mice were injected intraperitoneally with 200 g of
anti-CCR3 antibody once weekly from 20 to 30 weeks of
age. Inflamed controls mice were injected intraperitone-
ally with a nonspecific isotype control antibody for equal
duration. Mice were sacrificed 24 hours after final treat-
ments.
Tissue Collection and Histological and
Morphometric Analysis
Terminal ileal tissue was removed and fixed with 10%
neutral buffered formalin, processed, embedded in par-
affin, and cut into 5-m sections. Resulting sections were
stained with H&E (Sigma-Aldrich) according to the man-
ufacturer’s specifications, and a global inflammatory
score based on a quantitative index was assigned by a
pathologist blinded to the experimental conditions (P.J.),
as described previously.10,23 Briefly, three histological
parameters were assessed, with equal weight given to
each parameter: i) active inflammation (granulocyte infil-
tration, including neutrophils and eosinophils), ii) chronic
inflammation (lymphoplasmacytic infiltration), and iii) vil-
lus distortion (architectural disorder and separation of
villi, crypts, and muscularis propria). To assess goblet
cell hyperplasia, ileal sections were stained with PAS and
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counted and reported as a percentage of total villus
epithelial cells. Seven random high-power fields per
mouse were assessed for muscularis propria width, villus
and crypt length, and goblet cell numbers. A minimum of
21 measurements were made per intestinal section. The
most sensitive and accurate way to assess infiltrating
eosinophils is by eosinophil granule-specific immuno-
staining; here, we used a rat anti-mouse MBP monoclonal
as described previously.10 Sections were deparaffinized,
quenched of endogenous peroxidase, blocked with nor-
mal serum, and incubated with rat anti-mouse MBP1 an-
tibody (clone MT-14.7). Slides were washed and incu-
bated with biotinylated anti-rat antibody and avidin-biotin
complex (ABC) or avidin-biotin complex alkaline phos-
phatase (ABC-AP). All steps were performed while block-
ing endogenous biotin/avidin. Slides were developed ei-
ther by nickel diaminobenzidine, enhanced with cobalt
chloride or with permanent red substrate and counter-
stained with Methyl Green. Eosinophils were quantified
by standard area measurement to obtain the number of
eosinophils per high-power field, as described previ-
ously.10
Cell Isolation and Flow Cytometric Analysis
Splenocytes, mesenteric lymph nodes (MLN), and ileum
lamina propria (LP) mononuclear cells were isolated as
described previously.10 Fc receptor blockade was per-
formed with CD16/32 (no. 93; eBioscience, San Diego,
CA). Cells from indicated compartments were surface-
stained with fluorescently labeled antibodies directed
against IL-5R-FITC (T21), CCR3-AF647 (83103), Si-
glecF-PE (E50-2440) (BD Biosciences, San Jose, CA),
CD4-APC-Cy7 (GK1.5; BioLegend, San Diego, CA), and
CD8-eFluor450 (Ly-2), CD62L-PeCy7 (MEL-14), CD44-
FITC (IM7) (eBioscience), or corresponding isotype con-
trols. Fluorescence analysis was performed using a BD
FACSCanto II flow cytometer (BD Biosciences). Data files
were further analyzed using FlowJo software version 8.7
(Tree Star, Ashland, OR).
RNA and Real-Time Reverse Transcription
Polymerase Chain Reaction
Total RNA was prepared using an RNeasy mini kit (Qia-
gen, Valencia, CA), as described previously. For all gene
transcripts assessed, first-strand cDNA synthesis was
performed from 500 ng of total RNA using a high-capac-
ity cDNA archive kit (Applied BioSystems, Foster City,
CA). Transcript expression was assessed using TaqMan
gene expression assays with TaqMan probes (Applied
Biosystems). RT-PCR reactions were performed with AB-
solute Blue QPCR ROX mix (Thermo Scientific, Surrey,
UK), cDNA, and TaqMan assay mixtures. Thermocycling
and subsequent analysis were performed with an ABI
7300 real-time PCR instrument and ABI RQ software ver-
sion 1.4.4. Data were normalized to 18S expression and
were calculated for each sample as relative quantity RQ
 2Ct, where Ct is the cycle threshold. RQ values arepresented as fold change in mRNA expression relative to
controls.
Sircol Collagen Assay
Ileal collagen content was measured using a Sircol assay
kit (Biocolor, Carrickfergus, Northern Ireland, UK) ac-
cording to the manufacturer’s recommendations. Whole
ileal tissues were homogenized in tissue lysis buffer
(PBS) containing protease inhibitors (Roche Applied
Science, Indianapolis, IN) and phosphatase inhibitors
(Sigma-Aldrich). Total protein concentration was deter-
mined using the Bradford assay, with bovine serum al-
bumin as standard. Results are reported as nanograms
of total collagen per microgram of total ileal protein.
Statistical Analysis
Statistical analyses of data outcomes were performed
using a two-tailed Student’s t-test. Data are expressed as
means  SEM. Pearson’s correlation coefficient was
used to determine the relationship between eosinophil
number and histological measures of ileitis. A P value of
0.05 was used to determine statistical significance.
Results
Severity of Ileitis Correlates with Ileal
Eosinophilia
To determine whether eosinophilic inflammation was as-
sociated with inflammation and remodeling, intestinal eo-
sinophilia was measured in ileal tissues over the 40-week
time course. At 5 weeks of age, the ileal mucosa of
SAMP1 mice revealed no inflammation, similar to control
mice of the same age; SAMP1 mice also contained a
similar number of eosinophils as observed in uninflamed
controls (data not shown). Immunohistochemical staining
of tissues for MBP identified eosinophils predominantly in
the ileal mucosal and submucosal regions, with some
eosinophils infiltrating the muscular and serosal layers
(Figure 1A). Between 10 and 40 weeks of age, mice
developed progressive, transmural ileal inflammation10
consisting of mononuclear cells as well as eosinophils
(Figure 1B). This eosinophilic inflammation and remodel-
ing developed between 5 and 10 weeks of age; analysis
of 8-week-old mouse ilea from SAMP1 mice demon-
strated early progression of eosinophilia, inflammation,
and remodeling (data not shown). Eosinophil number
correlation with global histological inflammatory index
was performed at 5, 10, and 40 weeks of age; (r  0.92;
P  0.05) (Figure 1C). Cytokines and receptors associ-
ated with eosinophilia (ie, CCL11, CCL24, and CCR3)
increased during the time course, relative to age-
matched controls (Figure 1D).
Further characterization of ileal lamina propria eosino-
phil population was performed by flow cytometry. Gating
on the entire granulocyte forward scatter/side scatter
population demonstrated a significant increase in gran-
ulocytes in ileal lamina propria by 14 weeks of age
lamed v
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(SiglecFIL-5R) identified eosinophils within the gran-
ulocyte gate. A significant increase in SiglecFIL-5R
eosinophils was measured in both 14-week-old (20-
fold; P  0.06) and 30-week-old SAMP1 (4-fold; P 
0.004), relative to controls (Figure 2B). Gating on the
SiglecFIL5Ra eosinophils or SiglecFIL5R unde-
fined granulocyte populations from 30-week-old mice
demonstrated that the mean fluorescence intensity MFI
for CCR3 on SiglecF-positive granulocytes negative for
IL-5R was four times less than that of eosinophils posi-
tive for both SiglecF and IL-5R (P  0.001) (Figure 2C).
Thus, a population of SiglecFIL-5RCCR3high eosino-
phils is present in the lamina propria of 30-week-old
SAMP1 mice.
Histopathological Progression of Ileal
Remodeling and Intestinal Permeability in
Chronic Ileitis
Longitudinal development of remodeling in a sponta-
neous, chronic model of ileitis has not been examined
previously. By 10 weeks of age, our histological anal-
ysis documented significant ileal remodeling, com-
pared with uninflamed control mice (Figure 3A). These
histological observations persisted through the 40
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Figure 1. Eosinophilic inflammation in chronic eosinophilic ileitis. A: Repres
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ratios in inflamed mice were reduced/blunted to 1.5 
0.08 (P  0.001) and decreased to 0.6  0.05 (P 
0.001) by 40 weeks of age (Figure 3B). Hypertrophy of
the muscularis propria was significantly greater at 10
weeks of age in ileitis, compared with control mice
[150 m versus 50 m (P  0.001)], a finding that
persisted to 40 weeks of age (Figure 3D). This hyper-
trophy, due to reactive changes including cell swelling
and intercellular edema, was similar in both circular
and longitudinal muscle layers. Substantial increases
in goblet cell numbers were identified by PAS staining
(Figure 3C). Enumeration of percentage of goblet cells
per villus revealed a greater than twofold increase in
10-week-old mice with ileitis (P  0.001), progressing
to a greater than threefold increase by 40 weeks of age
(P  0.001), relative to uninflamed controls (Figure 3E).
Eosinophilia significantly correlated with increased
goblet cell component in villus epithelium (r  0.93;
P  0.01). Alterations in villus:crypt ratio, muscularis
propria width, and goblet cell hyperplasia were estab-
lished as early as 10 weeks of age. Villus blunting and
goblet cell hyperplasia were progressive and sus-
tained up to 40 weeks of age.
To assess the physiological effects of these histo-
logical changes over time, intestinal permeability was
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matched uninflamed controls, beginning at 20 weeks
of age (twofold increase; P  0.05) through to 40
weeks of age (six-fold increase; P  0.001) (Figure
3F). To elucidate whether the functional impairment is
associated with appearance of eosinophils, Pearson’s
correlation analysis between eosinophil numbers and
permeability was performed. Intestinal eosinophilia, al-
though not coincident with development of permeabil-
ity, covaried with increased permeability over the time
Figure 2. Flow cytometric examination of ileal eosinophilia. A: Represen
lamina propria cells from 14-week-old inflamed and control mice. FSC
30-week-old lamina propria cells show expansion of SiglecF and IL
double-positive (SiglecFIL-5R) eosinophils as determined by mean flu
0.001.course analyzed (r  0.83; P  0.08).Taken together, these results show an association be-
tween eosinophils and the development of chronic ileitis
and remodeling.
Remodeling-Associated Gene Expression Profile
Is Altered in Chronic Ileitis
Consistent with histological and functional analysis, molecular
markers of remodeling were notably increased. Quantitative
ensity scatter plots and quantification of flow cytometric analysis of ileal
d scatter; SSC, side scatter. B: Representative contour plots of 14- and
ileal eosinophils in inflamed mice. C: Expression levels of CCR3 on
ce intensity MFI. Data are expressed as means  SEM. *P  0.05; ***P tative d
, forwar
-5Rreal-time RT-PCR analysis revealed changes in genes related
20
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time in ileitis and when compared with control uninflamed
ileum (Table 1). Fibronectin mRNA levels were the most sig-
nificantly increased (24.5 3.5 fold change). Similar to ECM
molecules, the mesenchymal cytoskeletal marker -smooth
muscle actin (-SMA) was also significantly elevated (3.0 
0.4 fold change). Goblet cell-associated mucins were in-
creased over time, as were a number of remodeling-associ-
ated metalloproteinases and TGF- family ligands.
Corresponding analysis of total collagen protein by
Sircol assay revealed a significant increase, relative to
uninflamed control mice, at 40 weeks of age (15  0.06
versus 11  2 ng/g ileal tissue; P  0.05). Molecular
changes commenced by 10 weeks of age and devel-
oped through to 40 weeks of age.
Eosinophilia and Remodeling Decrease after
Dexamethasone Therapy
To begin to assess eosinophil effect on remodeling, a
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ment, histochemical and flow cytometric analysis showed
that ileal eosinophilia (Figure 4A), peripheral (ie, spleen)
inflammation (Figure 4B), and local MLN cellularity were
significantly reduced (Figure 4C). Along with diminished
inflammation, markers of tissue remodeling (including mus-
cularis hypertrophy and goblet cell hyperplasia) were sig-
nificantly attenuated, comparedwith saline-treated inflamed
controls (Figure 4, D and E). Thus, the broad-spectrum
anti-inflammatory dexamethasone successfully reduced
systemic inflammation, ileal eosinophilia, and remodeling in
this model of chronic eosinophilic ileitis.
Chronic Anti-CCR3 Antibody Administration
Attenuates Ileitis
To diminish the effect of eosinophils on ileal remodeling, we
used an antibody targeted at the chemotaxis receptor
CCR3.27 The present study therefore targeted the eosinophil
chemokine receptor CCR3. To directly assess the effect of
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villus:crypt ratios in the ileum from 10- to 40-week-
old mice. C: Representative PAS-stained ileal tissues
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and inflamedmice at 40weeks.D:Muscularis hyper-
trophy in the ileum from 10 to 40-week-old mice. E:
Quantification of the numbers of goblet cells as a
percentage of the total number of villus epithelial
cells from 10- to 40-week-old ilea. F: Intestinal per-
meability measured by FITC-labeled dextran (4 kDa)
method, presented as fold increase versus age-
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points, upon disease development (4 to 14 weeks of age) and
at chronic disease (20 to 30 weeks of age).25 When antibody
was administered from 4 to 10 weeks of age, during the time
when inflammation was developing, eosinophilia was re-
duced, relative to IgG-treated ileitis controls (78  8.9 versus
51  4.6 eosinophils per high-power field; P  0.01). This
pretreatment of ileitis targeted at eosinophilia also significantly
reduced overall histological indices of inflammation and
chronic architectural disruption (30%; P  0.05). When
weekly anti-CCR3 antibody infusions were administered from
20 to 30 weeks of age, during a time of maximal inflammation,
eosinophilic ileal inflammation was also significantly de-
creased, relative to IgG-treated ileitis controls (Figure 5, A and
B). This reduction in eosinophilia was found in all compart-
ments of ileal tissue, lamina propria through to muscle, with a
particular reduction in eosinophil accumulation at the basal
lamina region and approximately a 50% reduction in overall
tissue eosinophils per high-power field. Eotaxin 1 (CCL11) and
Table 1. Progressive Ileal Gene Expression Changes in Eosinoph
Gene 10 weeks 20
COL1A1 1.3  0.2 3.4 
COL1A2 1.3  0.3 2.4 
COL3A1 1.3  0.2 2.4 
COL4A1 1.4  0.3 2.2 
FN1 4.9  1.3 13.5 
ACTA2 1.2  0.1 1.5 
VIM 1.3  0.2 1.6 
CDH2 0.8  0.1 1.5 
MUC2 0.8  0.1 1.1 
MUC3A† 1.3  0.7 0.7 
MUC4 2.5  0.3*** 2.2 
MMP2 1.1  0.2 1.5 
MMP3 0.8  0.1 2.0 
MMP7 1.4  0.3 1.1 
MMP9 1.3  0.4 1.0 
MMP13 0.4  0.1 1.9 
TGFB1 1.4  0.2 1.5 
TGFB2 0.9  0.2 1.5 
TGFB3 1.2  0.2 1.6 
Data are expressed as mean fold change  SEM versus age-matche
*P  0.05, **P  0.01, and ***P  0.001, Student’s t-test.
†Previously MUC3.
Figure 4. Assessment of ileitis and remodeling after dexamethasone treatme
dexamethasone-treated SAMP1 mice. B and C: Absolute numbers for sple
muscularis width and percent goblet cells per villus from saline control and dex
means  SEM. *P  0.05; **P  0.01; ***P  0.001. n  4 per group.eotaxin 2 (CCL24) were significantly reduced after anti-eosi-
nophil targeted antibody treatment comparedwith IgG-treated
ileitis (Figure 5C; see also Supplemental Figure S1 at http://
ajp.amjpathol.org). Thismay be explained by the overall reduc-
tion in inflammatory infiltrate (Figure 6A), likely including re-
duced numbers of macrophages, which are the predominant
source of eotaxin in DSS colitis.7 In addition, as an indirect
molecular measure of reduced eosinophil presence in the
tissue,mRNAexpression of the eosinophil surfacemarker and
eotaxin receptor CCR3 was significantly reduced after treat-
ment.
Anti-CCR3 Antibody Treatment Results in
Decreased Severity of Ileal and Local Lymphoid
Inflammation
Absence of eosinophils in a lung model of eosinophil-
associated pathology (the OVA asthma model) resulted
itis
30 weeks 40 weeks
* 5.7  1.2*** 6.2  0.06**
* 4.8  0.8*** 4.2  0.7**
* 5.4  1.2*** 4.1  0.7**
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3.4  0.8** 1.6  0.3
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5.4  1.0*** 4.3  0.9*
2.8  1.1 3.1  0.5
* 2.1  0.2*** 1.6  0.1
2.3  0.4* 2.8  0.3**
2.7  0.3*** 1.8  0.3
flamed controls. n  5 per group.
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AJP November 2011, Vol. 179, No. 5in deficient recruitment of effector T cells and attenuated
pathology.28 We therefore sought to investigate the effect
of anti-CCR3 treatment on lymphocyte recruitment in this
chronic model of ileitis. After 10 weeks of anti-CCR3
antibody treatment (from 20 to 30 weeks of age), histo-
pathological indices of tissue inflammation were signifi-
cantly reduced, compared with IgG-treated mice (Figure
6A). Although splenic cellularity remained unchanged
after treatment, MLN cellularity was significantly de-
creased (Figure 6B). Characterization of the local MLN
cellularity identified a uniform and significant decrease in
CD4 (20%; P  0.001), CD8 (24%; P  0.05), and
CD19 (26%; P  0.001) lymphocytes (Figure 6C). Fur-
ther examination of T-lymphocyte populations revealed
Figure 5. Anti-CCR3 treatment attenuates ileal eosinophilia. Mice with es-
tablished ileitis were injected with isotype control (n  7) or anti-CCR3
antibody (n  6) weekly from 20 to 30 weeks of age. A: Representative
MBP-immunostained ileum localizes eosinophils with and without treatment
at 30 weeks of age. Scale bars 100 m. B: Eosinophilic infiltration into ileal
tissues was quantified using standard area measurements of MBP immuno-
staining. Data are presented as numbers of eosinophils per high-power field
(HPF). Data are expressed as means  SEM. ***P  0.001. n  6 or 7 per
group. C: Expression of three eotaxin family members was assessed in whole
ileal tissue total mRNA isolates after control or anti-CCR3 treatment, using
TaqMan qRT-PCR. Data are presented as mean fold change  SEM from
control treatments. n  6 or 7 per group.significant reduction in CD4 and CD8 effector T cells inanti-CCR3 treated tissues compared to IgG treated con-
trols (CD44highCD62Lneg: CD4 37%, P  0.05, and
CD8 50%, P  0.05), in addition to CD4 and CD8
central memory T cells (CD44highCD62Lhigh: CD4 44%,
P 0.01, and CD8 39%, P 0.001) after anti-eosinophil
treatment (Figure 6, D and E). In addition, molecular
characterization of immune function revealed a signifi-
cant reduction in IL-5 and IL-13 cytokine expression
(50% reduction; P  0.05) (Figure 6F; see also Supple-
mental Figure S1 at http://ajp.amjpathol.org). Finally, pre-
vious studies had determined a reduction in levels of
T- and B-lymphocyte chemokines in pulmonary inflam-
mation in mice congenitally deficient in eosinophils. We
sought to determine whether such a mechanism can
explain the reduction in lymphocyte recruitment in the
anti-CCR3-mediated reduction in eosinophils in this
mouse model of Crohn’s-like ileitis. A significant reduc-
tion in lymphocyte chemokines CCL17 (50%; P  0.05)
and CCL22 (50%; P  0.05) was observed, in addition to
reduction of CCR4 (50%; P  0.05), their cognate recep-
tor, on T- and B-lymphocytes in mice after anti-CCR3
treatment (Figure 6F; see also Supplemental Figure S1 at
http://ajp.amjpathol.org).
Attenuated Eosinophilia Is Sufficient to Reverse
Histological and Molecular Measures of Ileal
Remodeling
Similar to previous findings regarding the lung,19,25,29
targeted reduction of eosinophilia was associated with a
significant improvement in histological remodeling. Di-
minished goblet cell hyperplasia was observed, with
post-treatment levels reaching levels similar to those of
age-matched control uninflamed mice (Figure 7, A and
B). Muscularis width decreased, and villus:crypt ratios
reverted and approached normal ratios of age-matched
uninflamed control mice (Figure 7, C–E).
Similar to our findings from histological and cellular
investigations, analysis of previously measured mRNA
expression associated with remodeling revealed a con-
siderable reduction compared with IgG control-treated
ileitis. The most up-regulated gene, fibronectin, was sig-
nificantly reduced, as were a number of collagens, the
cytoskeletal molecules vimentin and -SMA, MMPs, and
the mesenchymal cell adhesion molecule N-cadherin
(Figure 7F; see also Supplemental Figure S1 at http://
ajp.amjpathol.org). Consistent with the histological mea-
sure of reduction in goblet cell hyperplasia, MUC2 and
MUC4 expression was significantly reduced after eosin-
ophil reduction (Figure 7F; see also Supplemental Figure
S1 at http://ajp.amjpathol.org). Functional assessment of
the mucosa revealed improvement in intestinal permea-
bility after treatment-induced restoration of tissue archi-
tecture. Permeability was reduced by 21%, compared
with IgG control-treated ileitis, after 10 weeks of anti-
CCR3 treatment (from 20 to 30 weeks of age). This find-
ing suggests a role for, but not a dependence on, eosin-
ophilia in the development of intestinal permeability in this
mouse model of ileitis.
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antibody-mediated reduction of eosinophilic burden
leads to significant reduction in overall inflammation and
remodeling in murine Crohn’s-like ileitis.
Discussion
Mucosal eosinophilia characterizes a number of chronic
diseases, including inflammatory bowel disease (IBD).
On stimulation, these granulated leukocytes can release
a number of proinflammatory and remodeling-associated
factors. Numerous mediators produced by eosinophils
have been associated with acute intestinal damage, and
recent evidence explicitly implicates these cells or their
products in chronic remodeling or fibrotic processes in
other locations in the intestinal tract. For instance, pa-
tients with eosinophilic esophagitis can develop stric-
tures, and in murine models of esophagitis develop IL-5-
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***dependent remodeling and fibrosis.20,30,31 In the presentstudy, we hypothesized that chronic eosinophilic inflam-
mation directly contributes to ileal remodeling in IBD. We
found that eosinophilic ileitis was associated with pro-
gressive histological, functional, and molecular markers
of remodeling. Pharmacological reduction of eosinophils
either by the broad-spectrum anti-inflammatory agent
dexamethasone or by specific antibody-mediated target-
ing via the CCR3 receptor decreased all of these indices.
Taken together, these findings support a role for eosino-
phils in chronic ileal remodeling.
Tissue remodeling is a vital process in the life cycle of
mucosal tissues. Tissue remodeling refers to the renova-
tive and/or adaptive process that develops to preserve
organ function during tissue homeostasis and in repair
after injury. Cellular and molecular features characteriz-
ing remodeling include goblet cell hyperplasia, muscular
hyperplasia and hypertrophy, neoangiogenesis, and ex-
tracellular matrix production, as well as changes in the
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AJP November 2011, Vol. 179, No. 5proteinase inhibitors. The same processes associated
with homeostatic tissue regeneration may lead to patho-
logical processes. Lack of control of tissue repair during
chronic inflammation may lead to intestinal stricture
formation. Thus, the fine balance between extracellular
matrix deposition and degradation defines the boundary
between health and disease.
Although the pathogenesis of IBD-related strictures is
unknown, a series of studies have provided some insight
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chymal cells by inflammatory responses to tissue injury.
Although fibroblasts are important mediators of fibrosis,
other cells also are critical to the remodeling process;
smooth muscle cells, recruited bone marrow stem cells
that differentiate into fibroblast-like cells, and epithelial
and endothelial cells in transdifferentiation to a mesen-
chymal state may all contribute to intestinal dysfunc-
tion.32 An important factor is exposure of intestinal mes-
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induce or suppress signaling of remodeling molecules
(including collagens, tissue inhibitors of metalloprotei-
nases, and MMPs). The production of chemokines may
also be key in a situation in which inflammation-associ-
ated fibrosis occurs. With the present study, we demon-
strate that disease progression is associated with in-
creased eosinophil-attracting chemokines CCL11 and
CCL24. This eosinophilic ileitis is also associated with an
increase in goblet cells and hypertrophy of the muscu-
laris propria. Increases in collagen, other ECM mole-
cules, MMPs, IL-13, and TGF- are also involved in
pathogenesis in this model. Inhibition of eosinophilia by
dexamethasone or by antibody-mediated methods leads
to a significant regression of these pathological re-
sponses in this chronic ileitis. Thus, our data support a
role for eosinophils in gastrointestinal remodeling in
chronic ileitis.
Various studies targeting the reduction of eosinophilia
have identified potential roles for eosinophils in remodel-
ing and fibrotic process in other organ systems.25,33–36
Inhibition of eosinophilic inflammation with anti-CCR3 an-
tibody resulted in a decrease in mucus accumulation and
diminution of airway hyperresponsiveness after airway
challenge in a sensitized mouse.25 In a pulmonary model
of airway injury, antibody inhibition of IL-5 led to improve-
ment in lung function and airway remodeling,37,38
whereas both PHIL and dblGATA mouse models genet-
ically deficient in eosinophils define a critical role for
eosinophils in allergic airway remodeling, one that in-
volves mucus, collagen, and smooth muscle accumula-
tion.35,36 Similarly, eosinophils are rich sources of TGF-,
and asthma patients with subepithelial fibrosis demon-
strate increased expression of eosinophil-derived TGF-
mRNA and protein.39 Patients with hypereosinophilic syn-
drome can develop endomyocardial fibrosis, a devastat-
ing complication, and a finding thought to be related to
eosinophil cationic protein.40 Treatment of asthma pa-
tients with anti-IL-5 mepolizumab revealed a significant
reduction of eosinophilia correlated with substantial re-
duction of subepithelial basement membrane thickness
and ECM expression in biopsies obtained from patients
after treatment.19 Consistent with these findings, the
present results revealed a reduction in goblet cells, re-
duced expression of numerous molecules associated
with remodeling, and diminished ECM production after
anti-eosinophil treatment.
Although eosinophils are closely linked with airway
remodeling, emerging evidence supports a role for
eosinophil participation in intestinal remodeling. For
instance, recent work examining the pathogenesis of
eosinophilic esophagitis showed the presence of pS-
MAD-positive TGF--positive eosinophils in remodeled
tissues.31 Murine models of eosinophilic esophagitis
have demonstrated the IL-5 dependency of collagen
deposition in inflamed tissues.30 Finally, chronic eosin-
ophilia is associated with isolated and long-segment
strictures in eosinophilic esophagitis. In support for the
role of eosinophils in ileitis, we observed a reduction in
IL-5 and TGF- after anti-eosinophil treatment. Re-
duced eosinophils in our model led to significant re-duction in ileal remodeling and a large set of associ-
ated molecules. Taken together, these results support
the eosinophil as a potential therapeutic target in pre-
vention of IBD-associated strictures.
The most dramatically increased molecule in remodel-
ing was the ECM component fibronectin. This molecule is
involved in the adhesion, retention, and potential activa-
tion of eosinophils in the interstitial space.41 Eosinophils
have been reported to induce the synthesis of fibronectin
in intestinal myofibroblasts,42 defining a direct role for
eosinophils in ECM production and in myofibroblast ac-
tivation, in addition to maintaining an environment suit-
able for eosinophil retention and activation. As shown in
previous studies examining lung injury, we found that
reduced eosinophils and thus remodeling mediators, in-
cluding fibronectin, led to a partial reversal of ileal inflam-
mation and remodeling.19,25,28,29
Eosinophils are well-known sources of functional IL-
13,43 a molecule associated with remodeling and fibro-
sis.44 For instance, a number of studies have highlighted
the role of IL-13 as a central mediator driving the major
asthmatic pathologies, including eosinophilia, mucus ac-
cumulation, fibrosis, and airway hyperresponsiveness.44
Parasite-mediated increases in intestinal IL-13 are critical
for intestinal goblet cell hyperplasia and mucus secretion
leading to worm expulsion and host protection.45 Ficht-
ner-Feigl et al46 determined that IL-13 induction is critical
in a model of chronic TGF-1-dependent tissue fibrosis
triggered by 2,4,6-trinitrobenzene-induced colitis. Our
previous work demonstrated increased IL-13 in SAMP1
ileal tissues,10 and here we report a progression of goblet
cell hyperplasia, muscle hypertrophy, and eosinophil ac-
cumulation over time in ileitis. Anti-eosinophil treatment
led to a decrease in IL-13 expression, as well as to
diminished ileal remodeling. Although this point is be-
yond the scope of the present study, eosinophil-derived
IL-13 may play a central role in the underlying pathogen-
esis of eosinophil-associated remodeling.
Mice congenitally deficient in eosinophils (PHIL and
dblGATA mice) show no alteration in normal circulating
lymphocyte numbers, and there is no effect on normal
leukocyte development.36,47 In the present study, eosin-
ophil attenuation resulted in a local, but not systemic,
decrease in lamina propria leukocytes, including T-effec-
tor memory and T-central memory lymphocytes. Of note,
defective recruitment of T-effector memory cells that re-
sulted in attenuated inflammation was described previ-
ously in the eosinophil-less PHIL mouse after OVA-chal-
lenge.28 In the PHIL model, the presence of eosinophils
was necessary for the expression of chemokines re-
quired for recruitment of effector T cells and the subse-
quent induction of pulmonary remodeling and tissue dys-
function. Recent studies of a model of allergic asthma in
dblGATA mice determined a critical role for eosinophil
derived IL-13 in the recruitment of T lymphocytes and the
development of airway hyperresponsiveness.48 Our find-
ings also demonstrate reduced lymphocyte chemokines
and IL-13 after treatment targeting eosinophils, suggest-
ing a similar critical role for eosinophils in the develop-
ment of intestinal inflammation and remodeling. Early
studies of SAMP1 models of ileitis suggest the central
IBD, Eosinophils, and Remodeling 2313
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recent evidence, however, may suggest a nonhemato-
poietic origin of inflammation.22 Thus, reduction in both
eosinophils and T cells is of importance for successful
treatment of disease in these SAMP1 models and may
point to a potential role for eosinophils in modulating the
local immune response in the intestine, however further
investigation is required.
Our previous work identified distinct differences be-
tween the ileal immune profile in the SAMP1 and the
SAMP1/YitFc model. The SAMP1 ileal cytokine profile
switched to a Th2 predominant profile with reduced to no
expression of Th1 cytokines, however the SAMP1/YitFc
remains predominantly Th1 with low levels of Th2 cyto-
kines.10 Early studies with the SAMP1/Yit model of ileitis
suggest the central role of T cells in the induction of
inflammation.15,49 Other evidence points to a nonhema-
topoietic origin of inflammation in the SAMP1/YitFc
model.22 Increased numbers of eosinophils are present
in both the SAMP1 and the SAMP1/YitFc ilea. Our data
support a functional role for eosinophils in the ileal mu-
cosa, associated in particular with remodeling events in
this SAMP1 Crohn’s-like mouse model of eosinophilic
ileitis.
Here, we have reported that eosinophils play a signif-
icant role in murine ileal remodeling and fibrosis. Further
studies are planned to address specific eosinophil-de-
rived mediators contributing to this response. Because
the pathogenesis of fibrosis and strictures in IBD is
largely unknown, our findings add to a growing body of
literature aimed at understanding this problem and may
add the eosinophil and eosinophil-derived mediators as
candidate targets for novel therapies for IBD-related
strictures.
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